Gallstones on a GLP-1 During Menopause: Why the Risk Doubles Up

They increase the risk, and the size of that increase is well quantified. The largest analysis to date pooled 76 randomized controlled trials covering 103,371 people and found that assignment to a GLP-1 receptor agonist was associated with a 37% higher relative risk of gallbladder or biliary disease (RR 1.37) compared with placebo or non-GLP-1 comparators (He et al., JAMA Internal Medicine, 2022).

Breaking that down by condition: cholelithiasis (gallstones sitting in the gallbladder) rose 27%, cholecystitis (an inflamed or infected gallbladder) rose 36%, and other biliary disease rose 55%.

Three patterns stood out. Risk was higher in trials studying weight loss rather than diabetes. Risk was higher at higher doses. And risk was higher with longer treatment duration. In other words, exactly the profile of someone on Wegovy or Zepbound for a year or more.

It is important to keep the absolute numbers in perspective. A 37% relative increase on a small baseline is still a modest absolute risk. Most people on a GLP-1 will never have a gallbladder problem. But if you are in the group that stacks multiple risk factors, it is worth understanding rather than ignoring. Our general overview of [GLP-1 gallbladder risk and symptoms](/blog/glp1-gallbladder-gallstones-risk-symptoms-what-to-know) covers the basics; this article focuses on what changes when menopause is in the picture.

Two mechanisms overlap, and they pull in the same direction.

The first is reduced gallbladder emptying. Your gallbladder is a small pouch that stores bile, the fluid your liver makes to digest fat. When fat hits your small intestine, a hormone called cholecystokinin signals the gallbladder to squeeze and release bile. GLP-1 medications slow gastric emptying and appear to blunt this squeeze. Bile that sits still for longer becomes more concentrated, and concentrated bile is where cholesterol crystals begin to form. This is the same reason prolonged fasting and IV nutrition are classic gallstone risk factors.

The second is eating far less fat. On a GLP-1, appetite drops, portions shrink, and rich foods often become unappealing. Many women end up eating very little dietary fat without deciding to. Less fat means less cholecystokinin, which means fewer gallbladder contractions, which means bile stagnates further. Undereating in general compounds this, which is why our guide to [the calorie floor on a GLP-1 in menopause](/blog/eating-enough-on-glp1-during-menopause-calorie-floor) matters here.

A third contributor is the weight loss itself, which we will come to. During rapid fat loss, the liver dumps extra cholesterol into bile, supersaturating it.

The practical takeaway: it is not that the medication is toxic to your gallbladder. It is that the gallbladder is an organ that needs to be used regularly, and a GLP-1 quietly reduces how often you use it.

Estrogen is a gallstone risk factor in its own right, which is why women have roughly twice the rate of gallstones that men do across adulthood. Estrogen increases the amount of cholesterol the liver secretes into bile, and progesterone reduces gallbladder motility. That combination, higher cholesterol in bile plus a lazier gallbladder, is the classic setup for stone formation.

This is directly relevant if you take hormone therapy. In the Women's Health Initiative, women randomized to estrogen therapy had a significantly higher rate of gallbladder events, including cholecystitis and cholecystectomy, than those on placebo. The effect is driven largely by the first-pass liver effect of oral estrogen: a pill is absorbed through the gut and passes through the liver in high concentration before reaching the rest of the body.

That detail matters, because transdermal estrogen bypasses first-pass metabolism. Observational data, including a large UK general-practice analysis published in the BMJ, found lower gallbladder disease risk with patches and gels than with oral estrogen. If you are on a GLP-1 and considering or already using HRT, delivery route is a conversation worth having with your prescriber. Our comparison of [patch vs pill vs gel](/blog/hrt-patch-vs-pill-vs-gel-which-is-safest) covers the trade-offs.

Age itself is also a factor. Gallstone prevalence rises steadily through the 40s, 50s and 60s, so the menopause transition is already the window where risk climbs, before you add anything else.

The threshold most often cited is 1.5 kg, or about 3 pounds, per week. Above that pace, gallstone formation rises sharply. Studies of very low calorie diets and bariatric surgery, where weight comes off fastest, have reported new gallstones in a substantial minority of patients within the first six months, though only a fraction develop symptoms.

Most people on a GLP-1 lose weight more gradually than that, which is genuinely protective. In the large phase 3 trials, average loss worked out to roughly 0.5 to 1 pound per week sustained over 68 to 72 weeks. The people at higher risk are those who lose very quickly early on, usually because appetite suppression is dramatic and they end up eating far below their needs.

This is one of several reasons not to rush dose escalation. If your weight is dropping faster than about 1% of body weight per week, or you are barely eating, that is a signal to slow down rather than a sign of success. Our guide to [when to increase your dose and when to hold](/blog/glp1-dose-escalation-when-to-increase-and-when-to-hold) walks through how to have that conversation with a prescriber.

In menopause specifically, losing too fast carries a second cost: muscle and bone loss. Estrogen decline already accelerates both, and aggressive calorie restriction compounds it. Steady loss protects your gallbladder, your muscle and your skeleton at the same time.

Classic gallbladder pain is called biliary colic. It shows up as a steady, intense ache or pressure in the upper right side of your abdomen, just under the ribs, or sometimes in the center just below the breastbone. It often radiates to the right shoulder blade or between the shoulders. It usually begins 30 minutes to a couple of hours after eating, especially a fatty meal, and can last anywhere from 15 minutes to several hours. Nausea and vomiting frequently come with it.

The tricky part on a GLP-1 is that nausea, upper abdominal discomfort and fullness are also common ordinary side effects. The features that distinguish gallbladder pain are that it is severe, comes in discrete episodes, is clearly located on the right side, and radiates to the back or shoulder. Routine GLP-1 nausea is duller, more diffuse and more constant.

Seek same-day care if you have upper right abdominal pain plus any of the following: fever or chills, yellowing of the skin or whites of the eyes (jaundice), dark urine with pale stools, pain lasting more than five hours, or persistent vomiting. Those suggest cholecystitis, a blocked bile duct or pancreatitis, all of which are urgent.

Diagnosis is straightforward: an abdominal ultrasound, sometimes with blood tests for liver enzymes and lipase. Tell whoever sees you that you are on a GLP-1 and how much weight you have lost, because it changes what they look for.

Five practical steps cover most of it.

1. Keep some fat in every meal. Aim for roughly 10 to 15 grams of fat per meal so your gallbladder contracts regularly. Olive oil, avocado, nuts, seeds, eggs, oily fish and full-fat dairy all work. Fat also slows the blood sugar curve and helps with satiety, which matters more in midlife.

2. Don't skip meals entirely. Long fasting windows let bile sit. If you are eating only once a day because of appetite suppression, that is worth flagging to your prescriber. Prolonged fasting patterns on a GLP-1 during menopause carry trade-offs beyond the gallbladder.

3. Keep weight loss under about 1% of body weight per week. Slower is safer for bile, muscle and bone.

4. Discuss estrogen delivery route. If you are on oral HRT and also on a weight-loss dose GLP-1, ask whether a patch or gel would suit you. This is not a reason to stop hormone therapy, which has real benefits for symptoms, bone and quality of life. It is a reason to choose the route thoughtfully.

5. Ask about ursodeoxycholic acid if you are high risk. Ursodiol has evidence for reducing gallstone formation during rapid weight loss and is sometimes prescribed prophylactically after bariatric surgery. Whether it makes sense for you is a clinical decision, not a self-treatment one.

One more thing worth saying plainly: gallbladder risk is a reason for attention, not a reason to abandon a medication that is helping your metabolic health. The same weight loss that briefly raises gallstone risk lowers your long-term risk of cardiovascular disease, fatty liver and diabetes.